Albany, NewYork (PRWEB) July 30, 2014
With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic reagent industry has been developing quickly, especially in vitro diagnostic reagents occupy over 90%. In 2013, Chinese in vitro diagnostics market size reached RMB22.98 billion, of which RMB16.61 billion came from in vitro diagnostic reagents.
Read complete report with TOC at http://www.researchmoz.us/china-diagnostic-reagent-industry-report-2013-2016-report.html.
Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013.
Currently, about 40%-50% share of the Chinese in vitro diagnostics market has been dominated by foreign companies represented by Roche, Siemens, Abbott and Johnson & Johnson. Although there are 300-400 local enterprises in China in vitro diagnostics industry, the top ten Chinese companies which rank by production scale only seize 30% market share, reflecting a low industry concentration degree.
Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.
Find more related article in Linkedin ar https://www.linkedin.com/today/author/137774108.
In 2014, a number of local Chinese diagnostic reagent companies (including BSBE, Maker Biotechnology, Health BioMed, Wondfo, Thalys) intend to step in the capital market through IPO because they are optimistic about the prospects of the diagnostic reagent industry; the raised funds will be used in the expansion of the existing projects or the construction of new projects. SHINVA, Humanwell Healthcare and Zhongyuan Union Stem Cell Bioengineering have entered the diagnostic reagent industry through acquisitions.
All latest market research report at http://www.researchmoz.us/latest-report.html.
Global Medical Laboratories Market 2014 - 2020
Medical laboratories are defined (http://www.researchmoz.us/medical-laboratories-market-global-industry-size-market-share-trends-analysis-and-forecasts-2012-2018-report.html) as the independent, commercial enterprises that provide information to the healthcare professionals about the severity, onset and reason of patients' physical ailments. Medical laboratories include biological, bacteriological, histological, pathological and chemical analysis, urinalysis and dental and medical X-rays. About 70% of the health care decisions taken by doctors for treatment of diseases are based on the results of laboratory testing which makes the medical laboratories a vital part of the global healthcare system.
Scleroderma Diagnostics And Therapeutics Market 2014 - 2020
Scleroderma, also known as systemic sclerosis (http://www.researchmoz.us/scleroderma-diagnostics-and-therapeutics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2014-2020-report.html) is a chronic systematic autoimmune disease of skin that results in hardening of skin. The exact cause of the disease is still unrevealed; however, scientists believe that genetic and environmental factors are the cause for systemic sclerosis. Mutations in human leukocyte antigen (HLA) are expected to be the most important mutation that is responsible for causing systemic sclerosis. Aromatic and chlorinated solvents, trichloroethylene, white spirits, silica and ketones are some of the environment components that are responsible in causing scleroderma. These factors result in scleroderma but in a small proportion.
For More Information Kindly Contact: